NeuroPace Inc (NPCE)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 23,520 | 22,524 | 21,060 | 19,256 |
| Cost of goods sold | 5,388 | 5,182 | 5,640 | 5,122 |
| Gross profit | 18,132 | 17,342 | 15,420 | 14,134 |
| Selling, general and administrative | - | 15,049 | 13,909 | 14,299 |
| Sales and marketing | 12,043 | - | - | - |
| Research and development | 6,845 | 7,440 | 5,754 | 6,065 |
| General and administrative | 6,068 | - | - | - |
| Total operating expenses | 24,956 | 22,489 | 19,663 | 20,364 |
| Loss from operations | -6,824 | -5,147 | -4,243 | -6,230 |
| Interest income | 718 | 793 | 754 | 762 |
| Interest expense | 2,059 | 2,153 | 2,182 | 2,166 |
| Other income (expense), net | -486 | -82 | 219 | 120 |
| Net loss and comprehensive loss | -8,651 | -6,589 | -5,452 | -7,514 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.26 | -0.21 | -0.19 | -0.26 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.26 | -0.21 | -0.19 | -0.26 |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) | 32,863,031 | 31,480,911 | 29,444,625 | 28,853,216 |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) | 32,863,031 | 31,480,911 | 29,444,625 | 28,853,216 |